Related Experiment Videos
[Somatostatin and ventricular function in liver cirrhosis]
F M de la Villa1, D Solano López, J Bóveda
1Departamento de Medicina, Hospital Civil de Bilbao.
Revista Clinica Espanola
|February 1, 1990
Summary
Somatostatin administration significantly decreased heart rate and ejection fraction in patients with liver cirrhosis and alcoholic hepatitis, indicating a negative inotropic effect. This study investigated cardiac function changes in these patient groups.
Area of Science:
- Cardiology
- Hepatology
- Nuclear Medicine
Context:
- Liver cirrhosis and alcoholic hepatitis can affect cardiovascular function.
- Assessing left ventricular function is crucial in managing these conditions.
Purpose:
- To evaluate the impact of somatostatin on left ventricular function in patients with liver cirrhosis and alcoholic hepatitis.
- To compare cardiac hemodynamic responses to somatostatin between patient groups and healthy controls.
Summary:
- Isotopic ventriculography (Tc99m) assessed basal left ventricular function and responses to somatostatin in cirrhotic and alcoholic hepatitis patients.
- Somatostatin significantly reduced heart rate, ejection fraction, and maximal ejection rate in both groups.
- A significant increase in left ventricular end-diastolic pressure was observed post-somatostatin, without altering systemic resistance.
Impact:
- The findings suggest somatostatin exerts a negative inotropic effect and causes bradycardia, impacting cardiac performance.
- Understanding these effects is vital for clinical management and potential therapeutic interventions in liver disease patients.